United Kingdom (UK)
Recombinant monoclonal antibody to CD155. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma CD155.16 .
UniProt Accession Number of Target Protein: P15151
Alternative Name(s) of Target: PVR; PVS; NECL-5; Poliovirus receptor; Nectin-like protein 5
Immunogen: The original antibody was generated by immunizing KAC mice (KAC mouse is a genetically engineered mouse strain that expresses BAP -Biotin Accepting Peptide, sequence on constant part of kappa chain) subcutaneously with CD155-Fc fusion protein.
Specificity: This antibody binds human CD155 also called the poliovirus receptor (PVR). The binding of this antibody does not block binding of TIGIT to CD155/PVR. This protein mediates NK cell adhesion and triggers NK cell function. It also binds two NK cell receptors CD96 and CD226. CD155 is gaining more interest as a therapeutic target in the field of tumor immunology due to its prominent endogenous and immune functions.
Application Notes: This antibody was used to identify CD155 expression on U-87 MG and U-87 MG PVRhi cell lines using flow cytometry. This antibody was used in the generation of anti-CD155 -saporin and anti-CD155-diphtheria immunotoxins and were tested for its antitumor activity. Cytotoxic effect was determined by ToxiLight kit. The results suggested that the immunotoxins were successful in killing CD155 expressing tumor cells.(WO2019102456).
Antibody first published in: PMID: